July 2008
Authors : M Florentin1 , EN Liberopoulos1 , DP Mikhailidis2 , Elisaf MS3
Affliation :
1University of Ioannina, Medical School, Department of Internal Medicine, Ioannina, Greece, Ioannina 45110, Greece
2Department of Clinical Biochemistry (Vascular Disease Prevention clinics), Royal Free Hospital, Royal Free and University College School of Medicine University of London, Pond Street, London, NW3 2QG, UK
3University of Ioannina, Medical School, Department of Internal Medicine, Ioannina 45110, Greece ; ; egepi@cc.uoi.gr
DOI : 10.1517/14656566.9.10.1705
Published in : Expert Opin. Pharmacother. Volume 9 Issue 10 2008 pages 1705 1720
Subject:
Keywords: adverse effects , diabetes , dipeptidyl peptidase 4 inhibitors , hypoglycemia , sitagliptin
Please Login to read the full article.
- Merck BioVentures: where biosimilars make a difference
- Chinese producers may be losing price edge to India, says Granules MD
